- Home
- OM vs LXEO Comparison
OM vs LXEO Comparison
Compare OM & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- LXEO
- Stock Information
- Founded
- OM 2003
- LXEO 2017
- Country
- OM United States
- LXEO United States
- Employees
- OM N/A
- LXEO N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- LXEO
- Sector
- OM Health Care
- LXEO
- Exchange
- OM Nasdaq
- LXEO Nasdaq
- Market Cap
- OM 220.8M
- LXEO 257.0M
- IPO Year
- OM 2020
- LXEO 2023
- Fundamental
- Price
- OM $14.20
- LXEO $4.90
- Analyst Decision
- OM Hold
- LXEO Strong Buy
- Analyst Count
- OM 1
- LXEO 7
- Target Price
- OM $22.00
- LXEO $15.29
- AVG Volume (30 Days)
- OM 315.6K
- LXEO 382.9K
- Earning Date
- OM 08-06-2025
- LXEO 08-14-2025
- Dividend Yield
- OM N/A
- LXEO N/A
- EPS Growth
- OM N/A
- LXEO N/A
- EPS
- OM N/A
- LXEO N/A
- Revenue
- OM $119,304,000.00
- LXEO N/A
- Revenue This Year
- OM $10.55
- LXEO N/A
- Revenue Next Year
- OM $11.87
- LXEO N/A
- P/E Ratio
- OM N/A
- LXEO N/A
- Revenue Growth
- OM 2.47
- LXEO N/A
- 52 Week Low
- OM $5.85
- LXEO $1.45
- 52 Week High
- OM $25.35
- LXEO $12.72
- Technical
- Relative Strength Index (RSI)
- OM 44.47
- LXEO 60.29
- Support Level
- OM $13.07
- LXEO $4.33
- Resistance Level
- OM $13.80
- LXEO $5.05
- Average True Range (ATR)
- OM 1.00
- LXEO 0.33
- MACD
- OM 0.20
- LXEO 0.01
- Stochastic Oscillator
- OM 40.48
- LXEO 73.18
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.